Abstract
The field of intracavitary therapy has progressed so rapidly over the last few years that this conference has the luxury of separate coverage for theory and experimental results. Other presentations will focus on the clinical and pharmacokinetic results of intracavitary trials, so I’ll focus mainly on the background and theory. In particular, I have been asked to cover those pharmacokinetic factors which led to the pursuit of intracavitary therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dedrick RL, Myers CE, Bungay PM, DeVita VT: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treatment Rep. 62: 1–11, 1978.
Sloane EM, Baum JG, Hubbard SM, Wittes RE: Cancer Treatment Reports 1959–1983: Background review and tabular compilationof most-cited articles. Cancer Treat. Rep. 68: 329–337, 1984.
Myers CE, Collins JM: Pharmacology of intraperitoneal chemotherapy. Cancer Investigation 1: 395–407, 1983.
Collins JM, Dedrick RL: Pharmacokinetics of Anticancer Drugs. In: Chabner BA (ed) Pharmacologic Principles of Cancer Treatment, W.B. Saunders, Philadelphia, 1982, pp 77–99.
Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT: High-volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. Cancer Chemother. Pharmacol 1:161–166, 1978.
Jones RB, Collins JM, Myers CE, Brooks AE, Hubbard SM, Balow JE, Brennan MF, Dedrick RL, DeVita VT: High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res. 41:55–59, 1981.
Dedrick RL, Flessner MF, Collins JM, Schultz JS: Is the peritoneum a membrane? ASAIO J. 5: 1–8, 1982.
Gianni L, Jenkins JF, Greene RF, Lichter AS, Myers CE, Collins JM: Pharmacokinetics of the hypoxic radiosensitizers misonidazole and desmethylmisonidazole after intraperitoneal administration in humans. Cancer Res. 43: 913–916, 1983.
Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW, Myers CE: Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res. 41: 1916–1922, 1981.
Dedrick RL, Zaharko DS, Bender RA, Bleyer WA, Lutz RJ: Pharmacokinetic considerations on resistance to anticancer drugs. Cancer Chemother. Rep. 59: 795–804, 1975.
Blasberg R, Patlak CS, Fenstermacher JD: Intrathecal chemotherapy: Brain tissue profiles after ventriculocisternal perfusion. J. Pharmacol. Exp. Ther. 195: 73–83, 1975.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Collins, J.M. (1984). Pharmacokinetic Rationale for Intracavitary Therapy. In: Howell, S.B. (eds) Intra-Arterial and Intracavitary Cancer Chemotherapy. Developments in Oncology, vol 26. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3843-7_4
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3843-7_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3845-1
Online ISBN: 978-1-4613-3843-7
eBook Packages: Springer Book Archive